Format

Send to

Choose Destination
Vaccine. 2015 Oct 5;33(41):5481-5487. doi: 10.1016/j.vaccine.2015.01.079. Epub 2015 Feb 8.

TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development.

Author information

1
European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Im Neuenheimer Feld 326 - 3.OG, 69120, Heidelberg, Germany.
2
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, 38124 Braunschweig, Germany.
3
National Institute for Biological Standards and Control, Department of Health-Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom.
4
Department of Parasitology, Biomedical Primate Research Centre, Lange Kleiweg 161, 2288 GJ Rijswijk, Netherlands.
5
Vaccine Formulation Laboratory, University of Lausanne, Chemin des Boveresses 155, Epalinges 1066, Switzerland.
6
Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, 123St. Stephens Green Dublin 2, Ireland.
7
Department of Immunology, Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany.
8
European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Im Neuenheimer Feld 326 - 3.OG, 69120, Heidelberg, Germany. Electronic address: odile.leroy@euvaccine.eu.

Abstract

TRANSVAC was a collaborative infrastructure project aimed at enhancing European translational vaccine research and training. The objective of this four year project (2009-2013), funded under the European Commission's (EC) seventh framework programme (FP7), was to support European collaboration in the vaccine field, principally through the provision of transnational access (TNA) to critical vaccine research and development (R&D) infrastructures, as well as by improving and harmonising the services provided by these infrastructures through joint research activities (JRA). The project successfully provided all available services to advance 29 projects and, through engaging all vaccine stakeholders, successfully laid down the blueprint for the implementation of a permanent research infrastructure for early vaccine R&D in Europe.

KEYWORDS:

Adjuvants; Animal Models; Biomarkers; European Research Infrastructures; FP7; Harmonisation; Research and Development; Services; Standardisation; Vaccine

PMID:
25667962
DOI:
10.1016/j.vaccine.2015.01.079
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center